Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 17;24(1):100.
doi: 10.1007/s10238-024-01354-8.

Epidemiology of malignant tumors in patients with pemphigus: an analysis of trends from 1955 to 2021

Yue Luo #  1 , Xiaoya Fei  1 , Mingxia Wang  1 , Han Yang  2 , Ying Zhang  1 , Yiran Chen  2 , Ying Luo  3 , Xiaojie Ding  2 , Chunjie Gao  1 , Fang Shen  1 , Ruiping Wang  1 , Bin Li  1   3 , Le Kuai  2 , Qi Zheng  4 , Miao Li  5 , Jiankun Song  6
Affiliations
Review

Epidemiology of malignant tumors in patients with pemphigus: an analysis of trends from 1955 to 2021

Yue Luo et al. Clin Exp Med. .

Abstract

Background: The incidence of malignant tumors has increased in patients with non-paraneoplastic pemphigus, although there has been no systematic analysis of global epidemiology.

Objective: To explore the epidemiology of various types of non-paraneoplastic pemphigus associated with malignant tumors.

Methods: Five databases from establishment through October 20, 2023, were searched. STATA SE 17 was used for the data analysis. Subgroup, meta-regression, and sensitivity analyses were used to evaluate the heterogeneity of pooled studies.

Results: A total of 6679 participants were included in our meta-analysis from 16 studies. The aggregated prevalence of tumors in patients diagnosed with pemphigus was 8%. The prevalence was 7% in patients with pemphigus vulgaris, 10% in those with pemphigus foliaceus, and 12% in individuals diagnosed with other types of pemphigus. The prevalence was 8% in Asia, 11% in Europe, and 8% in North America. From a country-specific perspective, patients with pemphigus from Israel, Greece, and Germany exhibited a higher prevalence of tumors at 11%. Furthermore, when categorized by the duration of the study period, the highest prevalence was observed in studies spanning 10 to 20 years, at 11%.

Conclusion: These findings demonstrate the incidence and prevalence of malignant tumors in patients with non-paraneoplastic pemphigus, which may achieve early detection and intervention, and then reduce mortality rates.

Keywords: Epidemiology; Malignant tumors; Pemphigus.

PubMed Disclaimer

Conflict of interest statement

We confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

Figures

Fig. 1
Fig. 1
Flow diagram according to PRISMA 2020 guidelines
Fig. 2
Fig. 2
Overall prevalence of malignant tumors in non-paraneoplastic pemphigus
Fig. 3
Fig. 3
Galbraith plot
Fig. 4
Fig. 4
The leave-one-out meta-analysis
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kridin K, Zelber-Sagi S, Khamaisi M, Cohen AD, Bergman R. Remarkable differences in the epidemiology of pemphigus among two ethnic populations in the same geographic region. J Am Acad Dermatol. 2016;75:925–30. - PubMed
    1. Hahn-Ristic K, Rzany B, Amagai M, Bröcker E, Zillikens D. Increased incidence of pemphigus vulgaris in southern Europeans living in Germany compared with native Germans. J Eur Acad Dermatol Venereol. 2002;16:68–71. - PubMed
    1. Ren Z, Narla S, Hsu DY, Silverberg JI. Association of serious infections with pemphigus and pemphigoid: analysis of the Nationwide Inpatient Sample. J Eur Acad Dermatol Venereol. 2018;32:1768–76. - PubMed
    1. Hertl M, Jedlickova H, Karpati S, Marinovic B, Uzun S, Yayli S, et al. Pemphigus. S2 Guideline for diagnosis and treatment–guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J European Acad Dermatol Venereol. 2015;29(3):405–14. - PubMed
    1. Eming R, Sticherling M, Hofmann SC, Hunzelmann N, Kern JS, Kramer H, et al. S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid. J Dtsch Dermatol Ges. 2015;13:833–44. - PubMed